Citations

Showing 10 of 108094 citations.

Sex difference in clinical and procedural outcomes in patients undergoing coronary atherectomy: a systematic review and meta-analysis
Thandra, Abhishek , Pajjuru, Venkata Siva Kumar , Jhand, Aravdeep , Ponamgi, Shiva , Ismayl, Mahmoud , Torres, Rosa Cruz, Narmi, Ann, Agarwal, Himanshu , Kanmanthareddy, Arun , Sharma, Arunima, Ismayl, Mahmoud , Sharma, Arunima

Mayo Clinic

Coronary Artery Disease | October 14, 2022 | Volume: 33 | Issue: 8 | Pages: 634-642

10.1097/mca.0000000000001187 | PMID 36238981 Get It

Background Rotational and orbital coronary atherectomy (CA) are commonly utilized to treat complex calcified coronary lesions. We conducted a meta-analysis to evaluate sex differences in procedural complications and clinical outcomes after CA. Methods PubMed, Google Scholar, and Cochrane databases were searched for all studies comparing sex differences in procedural and clinical outcomes following CA. The outcomes of interest were procedural complications (coronary dissection, stroke, major bleeding, coronary perforation, cardiac tamponade, and slow or no flow in target vessel) and the clinical outcomes (including early mortality, mid-term all-cause mortality, stroke, myocardial infarction, and target vessel revascularization). Pooled risk ratios (RRs) with their corresponding 95% confidence intervals (CIs) were calculated using the Mantel–Haenszel random-effects model. Results Six observational studies with 3517 patients (2420 men and 1035 women) were included in this meta-analysis. While there was no significant difference in the early mortality (RR, 1.14; 95% CI, 0.37–3.53; P = 0.83) between men and women, at a mean follow-up of 2.9 years, all-cause mortality was significantly higher in women (RR, 1.29; 95% CI, 1.11–1.49; P = 0.0009). Women had an increased risk of procedure-related stroke (RR, 3.98; 95% CI, 1.06–14.90; P = 0.04), coronary dissection (RR, 2.10; 95% CI, 1.23–3.58; P = 0.006), and bleeding (RR, 2.26; 95% CI, 1.30–3.93; P = 0.004), whereas the rates of coronary perforation, cardiac tamponade, and the risk of slow or no flow in the revascularized artery were similar in both. Conclusion In our analysis, women undergoing CA are at increased risk of mid-term mortality and procedure-related complications including stroke, coronary dissection, and major bleeding.
Evaluation of Bivalirudin Dosing in Pediatric Extracorporeal Membrane Oxygenation with Renal Insufficiency or Renal Replacement Therapy
Seelhammer, Troy G. , Yabrodi, Mouhammad, Beshish, Asaad , Byrnes, Jonathan W. , Hall, James O., Wang, Lu , Hamzah, Mohammed , Hamzah, Mohammed , Niebler, Robert A.

Mayo Clinic

ASAIO Journal | October 14, 2022 | Volume: 68 | Issue: 11 | Pages: e196-e203

10.1097/mat.0000000000001818 | PMID 36229032 Get It

Bivalirudin offers several important advantages of relevance to the management of extracorporeal membrane oxygenation (ECMO) patients. This multicenter retrospective analysis evaluated the bivalirudin dosing in pediatric ECMO and correlated these doses with the severity of renal dysfunction. A total of 75 patients were included in this analyses: estimated glomerular filtration rate (eGFR) > 60 ml/min/1.73 m2 (n = 29), eGFR 30–60 (n = 18), eGFR < 30 (n = 28), and of those 23 were on renal replacement therapy (RRT). The initial bivalirudin dose used to reach therapeutic anticoagulation in patients with eGFR > 60 was significantly higher than the dose required in those with renal impairment (0.25 mg/kg/hr in patients with eGFR > 60 and 0.19 mg/kg/hr in patients on RRT, 0.18 mg/kg/hr in patients with eGFR 30–60 and 0.13 mg/kg/hr in patients with eGFR < 30 with no RRT). Progressive dose escalations (two to threefold increase) were required to maintain therapeutic range over the initial 4 days of ECMO that coincided with improving renal creatinine clearance during that same time period. Establishing an initial starting dose of bivalirudin contingent upon eGFR is essential for the rapid achievement of target anticoagulation intensity. Further dose adjustments guided by laboratory monitoring is necessary given the dynamic changes in creatinine clearance following ECMO initiation.
Application of Deep Learning to IVC Filter Detection from CT Scans
Gomes, Rahul , Kamrowski, Connor , Mohan, Pavithra Devy, Senor, Cameron, Langlois, Jordan , Wildenberg, Joseph C. , Wildenberg, Joseph , Gomes, Rahul

Mayo Clinic

Diagnostics | October 13, 2022 | Volume: 12 | Issue: 10 | Pages: 2475

10.3390/diagnostics12102475 | PMID 36292164 Get It

IVC filters (IVCF) perform an important function in select patients that have venous blood clots. However, they are usually intended to be temporary, and significant delay in removal can have negative health consequences for the patient. Currently, all Interventional Radiology (IR) practices are tasked with tracking patients in whom IVCF are placed. Due to their small size and location deep within the abdomen it is common for patients to forget that they have an IVCF. Therefore, there is a significant delay for a new healthcare provider to become aware of the presence of a filter. Patients may have an abdominopelvic CT scan for many reasons and, fortunately, IVCF are clearly visible on these scans. In this research a deep learning model capable of segmenting IVCF from CT scan slices along the axial plane is developed. The model achieved a Dice score of 0.82 for training over 372 CT scan slices. The segmentation model is then integrated with a prediction algorithm capable of flagging an entire CT scan as having IVCF. The prediction algorithm utilizing the segmentation model achieved a 92.22% accuracy at detecting IVCF in the scans.
Application of a simple DNA damage model developed for electrons to proton irradiation
Matsuya, Yusuke , Kai, Takeshi , Parisi, Alessio , Yoshii, Yuji, Sato, Tatsuhiko , Parisi, Alessio

Mayo Clinic

Physics in Medicine & Biology | October 13, 2022 | Volume: 67 | Issue: 21 | Pages: 215017

10.1088/1361-6560/ac9a20 | PMID 36228611 Get It

Abstract Proton beam therapy allows irradiating tumor volumes with reduced side effects on normal tissues with respect to conventional x-ray radiotherapy. Biological effects such as cell killing after proton beam irradiations depend on the proton kinetic energy, which is intrinsically related to early DNA damage induction. As such, DNA damage estimation based on Monte Carlo simulations is a research topic of worldwide interest. Such simulation is a mean of investigating the mechanisms of DNA strand break formations. However, past modellings considering chemical processes and DNA structures require long calculation times. Particle and heavy ion transport system (PHITS) is one of the general-purpose Monte Carlo codes that can simulate track structure of protons, meanwhile cannot handle radical dynamics simulation in liquid water. It also includes a simple model enabling the efficient estimation of DNA damage yields only from the spatial distribution of ionizations and excitations without DNA geometry, which was originally developed for electron track-structure simulations. In this study, we investigated the potential application of the model to protons without any modification. The yields of single-strand breaks, double-strand breaks (DSBs) and the complex DSBs were assessed as functions of the proton kinetic energy. The PHITS-based estimation showed that the DSB yields increased as the linear energy transfer (LET) increased, and reproduced the experimental and simulated yields of various DNA damage types induced by protons with LET up to about 30 keV μ m −1 . These results suggest that the current DNA damage model implemented in PHITS is sufficient for estimating DNA lesion yields induced after protons irradiation except at very low energies (below 1 MeV). This model contributes to evaluating early biological impacts in radiation therapy.
Prognostic Implications of Exercise-Induced Hypertension in Adults With Repaired Coarctation of Aorta
Egbe, Alexander C. , Miranda, William R. , Jain, C. Charles , Borlaug, Barry A. , Connolly, Heidi M. , Borlaug, Barry A

Mayo Clinic

Hypertension | October 13, 2022 | Volume: 79 | Issue: 12 | Pages: 2796-2805

10.1161/hypertensionaha.122.19735 | PMID 36252107 Get It

Background: The purpose of this study was to assess the relationship between exercise-induced hypertension (EIH) and cardiovascular events, and to determine whether exercise blood pressure (BP) improved risk stratification in adults with repaired coarctation of aorta. Methods: Retrospective study of patients with repaired coarctation of aorta on antihypertensive therapy that underwent exercise testing and exercise test (2003–2019). BP was measured at rest in 3 different clinical settings and averaged to determine the resting BP. Indices of left ventricular function and afterload were obtained from the echocardiogram. EIH was defined as systolic BP >210 (males) or >190 (females) at peak exercise. Cardiovascular event was defined as atrial fibrillation, ventricular tachycardia, heart failure hospitalization, heart transplant, and cardiovascular death. Results: Of 327 patients (age 35±13 years), 116 (35%) had EIH. Although the resting BP was similar between patients with versus without EIH, the EIH group had higher pulsatile arterial load, more advanced left ventricular remodeling, and were less likely to be on angiotensin converting enzyme inhibitor/angiotensin receptor blocker. EIH was associated with cardiovascular events (hazard ratio, 1.06 [95% CI, 1.02–1.08]) independent of resting systolic BP, and improved prognostic accuracy above resting systolic BP ( C statistic, 0.671 [95% CI, 0.645–0.694] to 0.727 [95% CI, 0.709–0.750]; P =0.01). Angiotensin-converting enzyme inhibitor/angiotensin receptor blocker was associated with a lower risk of cardiovascular events. Conclusions: EIH was associated with cardiovascular events independent of resting BP, and patients receiving angiotensin-converting enzyme inhibitor/angiotensin receptor blocker had lower risk of cardiovascular events. These data suggest that exercise BP could be used to assess adequacy of antihypertensive therapy, and to guide titration of antihypertensive therapy.
Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study
Wang‐Gillam, Andrea , McWilliams, Robert R. , Suresh, Rama , Lockhart, A. Craig , Brown, Amberly , Breden, Marcus , Belle, Jad I. , Herndon, John M. , Bogner, Savannah J. , Tan, Benjamin , Boice, Nicholas , Acharya, Abhi , Abdiannia, Mina , Yoon, Harry H. , Zhu, Mojun , Aranha, Olivia , Herzog, Brett H. , Lim, Kian-Huat , McWilliams, Robert R , Suresh, Rama , Lockhart, Albert C , Brown, Amberly , Breden, Marcus , Belle, Jad I , Herndon, John , Bogner, Savannah J , Pedersen, Katrina , Tan, Benjamin , Boice, Nicholas , Acharya, Abhi , Abdiannia, Mina , Gao, Feng , Yoon, Harry H , Zhu, Mojun , Trikalinos, Nikolaos A , Ratner, Lee , Aranha, Olivia , Hawkins, William G , Herzog, Brett H , DeNardo, David G , Wang-Gillam, Andrea , Pedersen, Katrina S. , Gao, Feng , Trikalinos, Nikolaos A. , Ratner, Lee

Mayo Clinic

Clinical Cancer Research | October 13, 2022 | Volume: 28 | Issue: 24 | Pages: 5254-5262

10.1158/1078-0432.ccr-22-0308 | PMID 36228156 Get It

Abstract Purpose: Targeting focal adhesion kinase (FAK) renders checkpoint immunotherapy effective in pancreatic ductal adenocarcinoma (PDAC) mouse model. Defactinib is a highly potent oral FAK inhibitor that has a tolerable safety profile. Patients and Methods: We conducted a multicenter, open-label, phase I study with dose escalation and expansion phases. In dose escalation, patients with refractory solid tumors were treated at five escalating dose levels of defactinib and gemcitabine to identify a recommended phase II dose (RP2D). In expansion phase, patients with metastatic PDAC who progressed on frontline treatment (refractory cohort) or had stable disease (SD) after at least 4 months of standard gemcitabine/nab-paclitaxel (maintenance cohort) were treated at RP2D. Pre- and posttreatment tumor biopsies were performed to evaluate tumor immunity. Results: The triple drug combination was well-tolerated, with no dose-limiting toxicities. Among 20 treated patients with refractory PDAC, the disease control rate (DCR) was 80%, with one partial response (PR) and 15 SDs, and the median progression-free survival (PFS) and overall survival (OS) were 3.6 and 7.8 months, respectively. Among 10 evaluable patients in the maintenance cohort, DCR was 70% with one PR and six SDs. Three patients with SD came off study due to treatment- or disease-related complications. The median PFS and OS on study treatment were 5.0 and 8.3 months, respectively. Conclusions: The combination of defactinib, pembrolizumab, and gemcitabine was well-tolerated and safe, had promising preliminary efficacy, and showed biomarker activity in infiltrative T lymphocytes. Efficacy of this strategy may require incorporation of more potent chemotherapy in future studies.
Inspiratory and leg muscle blood flows during inspiratory muscle metaboreflex activation in heart failure with preserved ejection fraction
Hammer, Shane M. , Bruhn, Eric J., Bissen, Thomas G. , Muer, Jessica, Villarraga, Nicolas , Olson, Thomas P. , Smith, Joshua R. , Muer, Jessica D, Smith, Joshua R , Borlaug, Barry A.

Mayo Clinic

Journal of Applied Physiology | October 13, 2022 | Volume: 133 | Issue: 5 | Pages: 1202-1211

10.1152/japplphysiol.00141.2022 | PMID 36227167 Get It

Respiratory muscle dysfunction is thought to contribute to exercise intolerance in heart failure with preserved ejection fraction (HFpEF); however, the underlying mechanisms are unknown. In the present study, patients with HFpEF had greater increases in leg muscle vascular resistance index and greater decreases in leg muscle blood flow index compared with controls during inspiratory resistive breathing (to activate the metaboreflex). Furthermore, respiratory muscle blood flow index responses normalized to pressure generation during inspiratory resistive breathing were exaggerated in HFpEF compared with controls.
Suppression and Replacement Gene Therapy for KCNH2 -Mediated Arrhythmias
Bains, Sahej , Zhou, Wei , Dotzler, Steven M. , Martinez, Katherine , Kim, CS John, Tester, David J. , Ye, Dan , Ackerman, Michael J. , Bains, Sahej , Ye, Dan

Mayo Clinic

Circulation: Genomic and Precision Medicine | October 13, 2022 | Volume: 15 | Issue: 6 | Pages: No page available

10.1161/circgen.122.003719 | PMID 36252106 Get It

Background: KCNH2 -mediated arrhythmia syndromes are caused by loss-of-function (type 2 long QT syndrome [LQT2]) or gain-of-function (type 1 short QT syndrome [SQT1]) pathogenic variants in the KCNH2 -encoded K v 11.1 potassium channel, which is essential for the cardiac action potential. Methods: A dual-component “suppression-and-replacement” (SupRep) KCNH2 gene therapy was created by cloning into a single construct a custom-designed KCNH2 short hairpin RNA with ~80% knockdown (suppression) and a “short hairpin RNA-immune” KCNH2 cDNA (replacement). Induced pluripotent stem cell-derived cardiomyocytes and their CRISPR-Cas9 variant-corrected isogenic control (IC) induced pluripotent stem cell-derived cardiomyocytes were made for 2 LQT2- (G604S, N633S) and 1 SQT1- (N588K) causative variants. All variant lines were treated with KCNH2-SupRep or non-targeting control short hairpin RNA (shCT). The action potential duration (APD) at 90% repolarization (APD 90 ) was measured using FluoVolt voltage dye. Results: KCNH2-SupRep achieved variant-independent rescue of both pathologic phenotypes. For LQT2-causative variants, treatment with KCNH2-SupRep resulted in shortening of the pathologically prolonged APD 90 to near curative (IC-like) APD 90 levels (G604S IC, 471±25 ms; N633S IC, 405±55 ms) compared with treatment with shCT (G604S: SupRep-treated, 452±76 ms versus shCT-treated, 550±41 ms; P <0.0001; N633S: SupRep-treated, 399±105 ms versus shCT-treated, 577±39 ms, P <0.0001). Conversely, for the SQT1-causative variant, N588K, treatment with KCNH2-SupRep resulted in therapeutic prolongation of the pathologically shortened APD 90 (IC: 429±16 ms; SupRep-treated: 396±61 ms; shCT-treated: 274±12 ms). Conclusions: We provide the first proof-of-principle gene therapy for correction of both LQT2 and SQT1. KCNH2-SupRep gene therapy successfully normalized the pathologic APD 90 , thereby eliminating the pathognomonic feature of both LQT2 and SQT1.
Linaclotide Reduced Response Time for Irritable Bowel Syndrome With Constipation Symptoms: Analysis of 4 Randomized Controlled Trials
Lacy, Brian E. , Ford, Alexander C. , Bartolini, Wilmin , Shea, Elizabeth P., Bochenek, Wieslaw, Boinpally, Ramesh , Ford, Alexander C , Brenner, Darren M. , Wu, James X. , Almansa, Cristina

Mayo Clinic

American Journal of Gastroenterology | October 13, 2022 | Volume: 118 | Issue: 5 | Pages: 872-879

10.14309/ajg.0000000000002064 | PMID 36227782 Get It

INTRODUCTION: These post hoc analyses provide clinically relevant data concerning time to response for individual irritable bowel syndrome with constipation (IBS-C) symptoms after linaclotide use. METHODS: Time-to-response data were pooled from 4 randomized controlled trials. Response time for abdominal symptoms (pain, discomfort, and bloating) and complete spontaneous bowel movements (CSBMs) were analyzed using the Kaplan-Meier method; patients were categorized as early responders (≤4 weeks), late responders (>4–12 weeks), or nonresponders. RESULTS: Among 2,350 patients (1,172 placebo and 1,178 linaclotide 290 μg), >50% of patients with IBS-C who initiated linaclotide treatment experienced a decrease of ≥30% in abdominal pain, discomfort, or bloating within 3–4 weeks (median). The median time to achieving ≥3 CSBMs was 4 weeks. Although not all linaclotide-treated patients responded within 12 weeks, a late response occurred between 4 and 12 weeks in 1 in 6 patients for abdominal pain and in approximately 1 in 10 patients for CSBM frequency. Comparisons of early responders, late responders, and nonresponders for both response definitions indicated that women, Whites, and patients with less severe baseline abdominal symptoms were more likely to respond early. DISCUSSION: Although treatment responses with linaclotide occurred in >50% of patients with IBS-C within 4 weeks of treatment initiation, benefits for individual abdominal symptoms and/or CSBM frequency can still occur between 4 and 12 weeks. A lack of improvement in one symptom does not negate the possibility of response for others, highlighting the importance of discussing all symptoms with patients and not assuming treatment futility at 4 weeks.